Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Vericel (NASDAQ:VCEL) reported a 25% increase in total revenue to $51.3 million in the first quarter of 2024. The company achieved record revenue for MACI of $40.2 million and saw a 63% growth in Burn Care revenue. Adjusted EBITDA grew by 325%. The full-year 2024 revenue guidance was raised to $238-$242 million. Vericel had a strong start to the year with significant margin expansion and profitability growth, positioning the company well for continued growth. The company also reported positive progress in new product launches and market penetration.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
